Prescribing Information including Boxed WARNINGS
Medication Guide
INDICATION
INDICATION
ELIQUIS (apixaban) is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem.
AFib=atrial fibrillation.
AFib increases the risk of stroke about 5x*
ELIQUIS is a treatment option that may reduce the risk of stroke for patients with AFib not caused by a heart valve problem.
*AFib not caused by heart value problem.
AFib=atrial fibrillation.
In a clinical study of adult patients with AFib not caused by a heart valve problem,
ELIQUIS was proven better than warfarin:
ELIQUIS and other blood thinners increase the risk of bleeding, which can be serious, and may lead to death. In another study compared to aspirin, ELIQUIS had a modest increase in major bleeding.†
In the same clinical study
over 97% of patients taking ELIQUIS did not experience a stroke
In a study with an average treatment time of 1.7 years, stroke occurred in 2.9% of warfarin patients vs. 2.3% of ELIQUIS patients.
Based on extensive clinical research
ELIQUIS was proven effective
ELIQUIS was evaluated in a clinical study to evaluate stroke risk reduction in adult patients with AFib not caused by a heart valve problem. Clinical study results are important because they can help doctors consider and choose the right treatment for you based on their efficacy and safety results.
~18,000
patients participated in the study
>9,000
patients took ELIQUIS
The study compared ELIQUIS to warfarin in patients with AFib not caused by a heart valve problem. This group also had at least one additional risk factor for stroke (a prior stroke, age 75 or older, diabetes, heart failure, high blood pressure).
In the study, ELIQUIS had significantly less major bleeding than warfarin.
Based on extensive clinical research
ELIQUIS was proven effective
ELIQUIS was evaluated in a clinical study to evaluate stroke risk reduction in adult patients with AFib not caused by a heart valve problem. Clinical study results are important because they can help doctors consider and choose the right treatment for you based on their efficacy and safety results.
~18,000
patients participated in the study
>9,000
patients took ELIQUIS
The study compared ELIQUIS to warfarin in patients with AFib not caused by a heart valve problem. This group also had at least one additional risk factor for stroke (a prior stroke, age 75 or older, diabetes, heart failure, high blood pressure).
In the study, ELIQUIS had significantly less major bleeding than warfarin.
Start a conversation about ELIQUIS
Get a Doctor Discussion Guide to help you talk with your doctor about AFib-related stroke risk not caused by a heart valve problem and whether ELIQUIS may be right for you.